Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2006.09.7535 on July 2 2007

Journal of Clinical Oncology, Vol 25, No 23 (August 10), 2007: pp. 3415-3420
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roché, H.
Right arrow Articles by Curé, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roché, H.
Right arrow Articles by Curé, H.
Related Articles
Right arrowRelated Editorial

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy

Henri Roché, Louise Yelle, Francesco Cognetti, Louis Mauriac, Craig Bunnell, Joseph Sparano, Pierre Kerbrat, Jean-Pierre Delord, Linda Vahdat, Ronald Peck, David Lebwohl, Rana Ezzeddine, Hervé Curé

From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Université de Montréal–Hôpital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill Medical College of Cornell University, New York, NY; and Bristol-Myers Squibb, Wallingford, CT

Address reprint requests to Henri Roché, MD, Institut Claudius Regaud, 20-24 rue du Saint Pierre, 31052 Toulouse Cedex, France; e-mail: roche.henri{at}claudiusregaud.fr

Purpose: There is a need for new agents to treat metastatic breast cancer (MBC) in patients for whom anthracycline therapy has failed or is contraindicated. This study was conducted to assess the efficacy and safety of the novel antineoplastic, the epothilone B analog ixabepilone, in patients with MBC previously treated with an adjuvant anthracycline.

Patients and Methods: Patients were age ≥ 18 years and had received a prior anthracycline-based regimen as adjuvant treatment. Ixabepilone as first-line metastatic chemotherapy was administered as a 40 mg/m2 intravenous infusion during 3 hours every 3 weeks. The primary efficacy end point was objective response rate (ORR). Secondary efficacy end points included duration of response, time to response, time to progression, and survival.

Results: All 65 patients were assessable for response. Their median age was 52 years (range, 33 to 80 years). ORR was 41.5% (95% CI, 29.4% to 54.4%), median duration of response was 8.2 months (95% CI, 5.7 to 10.2 months), and median time to response was 6 weeks (range, 5 to 17 weeks). Median survival was 22.0 months (95% CI, 15.6 to 27.0 months). Treatment-related adverse events were manageable and mostly grades 1/2: the most common of these (other than alopecia) was mild to moderate neuropathy, which was primarily sensory and mostly reversible in nature.

Conclusion: Ixabepilone is efficacious and has a predictable and manageable safety profile in women with MBC previously treated with an adjuvant anthracycline.

published online ahead of print at www.jco.org on July 31, 2006.

Supported by Bristol-Myers Squibb Co.

Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002, Orlando, FL; 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL; International Union Against Cancer Meeting, 2006; and Roché H, Perez E, Llombart-Cussac A, et al: Ixabepilone, an epothilone analog, is effective in ER-, PR-, HER2-negative (triple-negative) patients: data from neoadjuvant and metastatic breast cancer trials. Ann Oncol 17:ix93-ix113, 2006 (abstr 256-P).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Editorial

  • Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs
    Luca Gianni
    JCO 2007 25: 3389-3391 [Full Text]


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
S. Bhushan and C. M Walko
Ixabepilone: A New Antimitotic for the Treatment of Metastatic Breast Cancer
Ann. Pharmacother., September 1, 2008; 42(9): 1252 - 1261.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Goel, G. L. Goldberg, D. Y.-S. Kuo, F. Muggia, J. Arezzo, and S. Mani
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone
Ann. Onc., July 21, 2008; (2008) mdn420v1.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. Goodin
Novel cytotoxic agents: Epothilones
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S10 - S15.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. J. Lee and S. M. Swain
The Epothilones: Translating from the Laboratory to the Clinic
Clin. Cancer Res., March 15, 2008; 14(6): 1618 - 1624.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
L. Vahdat
Ixabepilone: A Novel Antineoplastic Agent with Low Susceptibility to Multiple Tumor Resistance Mechanisms
Oncologist, March 1, 2008; 13(3): 214 - 221.
[Abstract] [Full Text] [PDF]


Home page
JWatch Oncology and HematologyHome page
The Epothilones Are Coming!
Journal Watch Oncology and Hematology, August 28, 2007; 2007(828): 1 - 1.
[Full Text]


Home page
JCOHome page
L. Gianni
Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs
J. Clin. Oncol., August 10, 2007; 25(23): 3389 - 3391.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online